Programme
Accelerate Alumni (Cohort 4)
Founded in
2017
Total funds raised
£2.9 million
Employees
1-10
Industry
Healthcare, pharma, biotech
Spirea, a spinout from the University of Cambridge, is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells resulting in greater efficacy and tolerability and the ability to treat more cancer patients.
Get in touch
News about Spirea
Entrepreneurship and innovation
Cambridge startups innovate in cancer detection, therapy and drug delivery
Ventures mentored at the Accelerate Cambridge programme are tackling the disease from various angles.
Research centre news
From medicine to nutrition, celebrating innovation in Cambridge
Seven ventures or people with ties to the Entrepreneurship Centre at Cambridge Judge Business School are named in the #21toWatch list of science and tech talent in and around Cambridge.
Misc news
Women biotech leaders
Dr Rebecca Myers of the Entrepreneurship Centre at Cambridge Judge is included in the Movers and Shakers in BioBusiness 2020 report by the BioBeat project.